KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.99

Efficacy of immune checkpoint inhibitors in female patients with cancer: a systematic review and meta-analysis.

Jingjing Liu, Peng Wu, Dongyu Li, Xuanyu Gu, Bohui Zhao, Ruijie Ma, Binghua Tan, Dexin Shang, Yue Wu, Junhan Zhou, Chuqi Lin, Nan Sun, Chaoqi Zhang, Jie He

Sci China Life Sci 10.1007/s11427-025-3225-1

PMID42752777
PMCID-
DOI10.1007/s11427-025-3225-1
发表日期2026-09-17
入排依据:记录类型属于综述、Meta 分析、社论、评论、病例或指南。
摘要

摘要

Immune checkpoint inhibitors (ICIs) have transformed advanced cancer management by providing durable responses and significant survival benefits. However, sex-based differences in treatment outcomes remain poorly understood. In this systematic review and meta-analysis of 78 phase III randomized controlled trials including 56,332 patients, we specifically assessed the efficacy of ICIs in female patients. Overall, female patients experienced a overall survival (OS) benefit from immunotherapy (hazard ratio (HR)=0.80, 95% confidence interval (CI): 0.76-0.84, P<0.0001), although considerable heterogeneity was observed across studies. Subgroup analyses showed no statistically significant differences in OS benefit across the examined stratification factors. Notably, we found female with squamous cell carcinoma did not demonstrate a statistically significant survival benefit from ICIs (HR=0.86, 95% CI: 0.71-1.04). Male patients demonstrated a more pronounced benefit (HR=0.77, 95% CI: 0.74-0.80, P<0.0001), although no improvement was noted in melanoma and glioblastoma. These findings highlight meaningful sex-based disparities in immunotherapy efficacy and underscore the need to integrate sex as a biological variable in clinical decision-making. Greater inclusion of women in clinical trials, identification of sex-specific biomarkers, and development of tailored strategies are essential to optimize immunotherapy outcomes and advance personalized cancer care.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。